Prevention of Cancer
Early Detection Improves Survival Rates
Cancer screening and early detection significantly enhance survival rates, particularly when cancer is diagnosed at an earlier stage. For instance, the 5-year survival rate is 94.3% for Stage I but drops to 11.7% for Stage IV. Early screening using germline sequencing can identify individuals at higher risk, allowing for proactive prevention and timely intervention.
Personalized Screening for High-Risk Individuals
Germline testing, such as MammoReady™ for breast cancer and the Hereditary Cancer Panel, identifies individuals with inherited cancer risks. These tests are particularly beneficial for those with a family history of cancer, providing precise risk assessments to support preventive measures and early screening.
Clinically Validated & Highly Accurate Testing
Our tests deliver 100% sensitivity and 99.9% specificity, aligning with the latest NCCN guidelines for breast, ovarian, colorectal, pancreatic, and prostate cancers. Through targeted screening based on genetic risk profiles, 51% more cancers can be detected compared to random screening.
